Pfizer (PFE) Gross Margin (2016 - 2025)
Historic Gross Margin for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to 74.95%.
- Pfizer's Gross Margin rose 46800.0% to 74.95% in Q3 2025 from the same period last year, while for Sep 2025 it was 103.65%, marking a year-over-year increase of 432200.0%. This contributed to the annual value of 71.94% for FY2024, which is 138500.0% up from last year.
- Latest data reveals that Pfizer reported Gross Margin of 74.95% as of Q3 2025, which was up 46800.0% from 74.22% recorded in Q2 2025.
- Pfizer's Gross Margin's 5-year high stood at 79.26% during Q1 2025, with a 5-year trough of 120.24% in Q4 2023.
- Over the past 5 years, Pfizer's median Gross Margin value was 69.55% (recorded in 2022), while the average stood at 45.68%.
- Per our database at Business Quant, Pfizer's Gross Margin plummeted by -958000bps in 2023 and then soared by 1120000bps in 2024.
- Pfizer's Gross Margin (Quarter) stood at 58.68% in 2021, then grew by 25bps to 73.22% in 2022, then plummeted by -264bps to 120.24% in 2023, then skyrocketed by 158bps to 70.27% in 2024, then grew by 7bps to 74.95% in 2025.
- Its last three reported values are 74.95% in Q3 2025, 74.22% for Q2 2025, and 79.26% during Q1 2025.